Case Study: a leading biopharma company reduces immunogenicity testing time with Quantiphi’s DART platform

a leading biopharma company reduces immunogenicity testing time by 70% with Quantiphi

A leading Indian biopharmaceutical company faced significant challenges in its biosimilar development process due to its heavy reliance on animal models for immunogenicity assessment. These models provided poor human translatability, inconsistent results, and were costly and time-consuming. The client partnered with Quantiphi to find a modern, human-relevant alternative that could meet new regulatory demands for New Approach Methodologies (NAMs).

Quantiphi implemented its DART platform, which combines human Microphysiological Systems with AI-driven computer vision and deep learning models. This solution provided automated, human-relevant immunogenicity data from a compact benchtop workstation. The results for the biopharma company were substantial, including a 70% reduction in testing time, 100% human-relevant modeling, significant cost savings, and the early detection of immune responses. Quantiphi's solution also enabled scalable, in-house testing operations.